PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.48%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-4.83%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-19.44%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-19.44%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-25.60%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-25.00%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-25.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-0.05%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.00%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
-7.60%
Negative OCF growth while META is at 21.13%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
24.65%
FCF growth under 50% of META's 64.89%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
498.52%
10Y revenue/share CAGR under 50% of META's 1672.63%. Michael Burry would suspect a lasting competitive disadvantage.
128.10%
5Y revenue/share CAGR under 50% of META's 447.59%. Michael Burry would suspect a significant competitive gap or product weakness.
77.46%
3Y revenue/share CAGR under 50% of META's 183.80%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
384.02%
10Y OCF/share CAGR under 50% of META's 2218.77%. Michael Burry would worry about a persistent underperformance in cash creation.
164.52%
Below 50% of META's 558.24%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
55.02%
3Y OCF/share CAGR under 50% of META's 216.11%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
324.47%
Below 50% of META's 795.97%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
86.66%
Below 50% of META's 245.43%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
56.54%
3Y net income/share CAGR 1.25-1.5x META's 42.07%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
457.74%
Equity/share CAGR of 457.74% while META is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
93.63%
Below 50% of META's 369.73%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
46.88%
3Y equity/share CAGR at 50-75% of META's 85.89%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.12%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-4.88%
Inventory is declining while META stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
5.39%
Asset growth well under 50% of META's 12.48%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
3.35%
75-90% of META's 3.86%. Bill Ackman advocates improvements in profitability or buybacks to keep pace in net worth growth.
205.88%
Debt shrinking faster vs. META's 1342.00%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
-0.08%
Our R&D shrinks while META invests at 0.18%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-15.84%
We cut SG&A while META invests at 76.71%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.